Literature DB >> 1768820

Anesthesia for elective cardioversion: a comparison of four anesthetic agents.

R Canessa1, G Lema, J Urzúa, J Dagnino, M Concha.   

Abstract

Elective cardioversion is a short procedure performed under general anesthesia for the treatment of cardiac dysrhythmias. Selection of the anesthetic agent is important, because a short duration of action and hemodynamic stability are required. Forty-four patients scheduled for elective cardioversion in the coronary care unit were studied prospectively. All patients were randomly assigned, according to the last digit of their clinical record number, to receive one of the four anesthetic agents studied: group 1, 12 patients who received 3 mg/kg of sodium thiopental; group 2, 10 patients who received 0.15 mg/kg of etomidate; group 3, 12 patients who received 1.5 mg/kg of propofol; and group 4, 10 patients who received 0.15 mg/kg of midazolam. All patients also received 1.5 micrograms/kg of fentanyl 3 minutes before induction. All four drugs provided satisfactory anesthesia for cardioversion and there were no major complications. Midazolam produced a more prolonged duration of effect and more interindividual variability. Propofol was associated with hypotension and a higher incidence of apnea, and its duration of action was similar to that of etomidate or thiopental. Etomidate produced myoclonus and pain on injection; however, it was the only agent that did not decrease arterial blood pressure. Thiopental reduced blood pressure but otherwise seemed an appropriate anesthetic for this procedure. In conclusion, all four anesthetic agents were acceptable for cardioversion, although their pharmacological differences suggest specific indications for individual patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768820     DOI: 10.1016/1053-0770(91)90007-g

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  11 in total

Review 1.  [Implantation of cardioverter-defibrillators. How much anesthesia is necessary?].

Authors:  T Sellmann; M Winterhalter; U Herold; P Kienbaum
Journal:  Anaesthesist       Date:  2010-06       Impact factor: 1.041

Review 2.  Best evidence topic report. Procedural sedation for cardioversion.

Authors:  Jeremy Wood; Craig Ferguson
Journal:  Emerg Med J       Date:  2006-12       Impact factor: 2.740

Review 3.  Anaesthetic and sedative agents used for electrical cardioversion.

Authors:  Sharon R Lewis; Amanda Nicholson; Stephanie S Reed; Johnny J Kenth; Phil Alderson; Andrew F Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-03-22

4.  A dedicated cardioversion unit for the treatment of atrial fibrillation. Reducing costs by optimizing processes.

Authors:  C Knackstedt; M Becker; K Mischke; R Pauling; H P Brunner-La Rocca; P Schauerte
Journal:  Herz       Date:  2011-11-19       Impact factor: 1.443

Review 5.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 6.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

7.  Safe and effective use of conscious sedation for defibrillation threshold testing during ICD implantation.

Authors:  Ahmed Al Fagih; Hitham Al Shurafa; Saleh Al Ghamdi; Khaled Dagriri; Ayman Al Khadra
Journal:  J Saudi Heart Assoc       Date:  2010-08-08

Review 8.  Cardiac electrophysiology and conduction pathway ablation.

Authors:  J Renwick; C Kerr; R McTaggart; J Yeung
Journal:  Can J Anaesth       Date:  1993-11       Impact factor: 5.063

9.  Prevention of etomidate-related myoclonus in anesthetic induction by pretreatment with magnesium.

Authors:  Bulent Un; Dilek Ceyhan; Birgul Yelken
Journal:  J Res Med Sci       Date:  2011-11       Impact factor: 1.852

Review 10.  Sedation in the Electrophysiology Laboratory: A Multidisciplinary Review.

Authors:  Neal S Gerstein; Andrew Young; Peter M Schulman; Eric C Stecker; Peter M Jessel
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.